The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effectiveness of first- or second-line bevacizumab (BV) treatment (tx) in elderly patients (pts) with metastatic colorectal cancer (mCRC) in ARIES, an observational cohort study (OCS).
M. Kozloff
Consultant or Advisory Role - Genentech
Honoraria - Genentech
T. S. Bekaii-Saab
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Genentech
Honoraria - Amgen; Bristol-Myers Squibb; Genentech; Onyx
Research Funding - Pfizer
J. C. Bendell
Research Funding - Genentech
A. L. Cohn
No relevant relationships to disclose
H. Hurwitz
Consultant or Advisory Role - Genentech
Honoraria - Roche
Research Funding - Genentech
N. Roach
Consultant or Advisory Role - Genentech
Research Funding - Genentech
H. Tezcan
No relevant relationships to disclose
S. Fish
Employment or Leadership Position - Genentech
Stock Ownership - Roche
E. D. Flick
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Y. Mun
Employment or Leadership Position - Genentech
Stock Ownership - Roche
D. Dalal
Employment or Leadership Position - Genentech
Stock Ownership - Roche
A. Grothey
Consultant or Advisory Role - Amgen; Bayer; Genentech; ImClone Systems
Research Funding - Bayer; Daiichi Sankyo; Genentech